Campath update
Posted: Wed Jul 12, 2006 5:37 am
An update on campath from Genezyme's quarterly results press release...
Preparations are underway for the initiation of a phase 3 study of alemtuzumab (Campath) for the treatment of relapsing/remitting multiple sclerosis, which is expected during the second half of this year. In addition, nearly all participating patients have now completed at least 24 months in the ongoing Phase 2 clinical trial comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment of multiple sclerosis. Genzyme expects to release data in the second half of this year from a two-year interim analysis of this three-year study.
http://www.prnewswire.com/cgi-bin/stori ... 503&EDATE=
Preparations are underway for the initiation of a phase 3 study of alemtuzumab (Campath) for the treatment of relapsing/remitting multiple sclerosis, which is expected during the second half of this year. In addition, nearly all participating patients have now completed at least 24 months in the ongoing Phase 2 clinical trial comparing alemtuzumab with Rebif (interferon beta-1a) for the treatment of multiple sclerosis. Genzyme expects to release data in the second half of this year from a two-year interim analysis of this three-year study.
http://www.prnewswire.com/cgi-bin/stori ... 503&EDATE=